Last updated on September 2018

Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)

Brief description of study

The purpose of this study is to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) subjects with Programmed death ligand 1+ (PD-L1+) tumors

Clinical Study Identifier: NCT02576574

Contact Investigators or Research Sites near you

Start Over

Tatsuo Ohira

Tokyo Medical University Hospital
Shinjuku-ku, Japan
  Connect »

Hidehito Horinouchi

National Cancer Center Hospital
Chuo-ku, Japan
  Connect »